Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis

Ya-kai Huang, Jian-chun Yu*, Wei-ming Kang, Zhi-qiang Ma, Xin Ye, Shu-bo Tian, Chao Yan

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* yjcpumch@126.com

Abstract

Background
Human pepsinogens are considered promising serological biomarkers for the screening of atrophic gastritis (AG) and gastric cancer (GC). However, there has been controversy in the literature with respect to the validity of serum pepsinogen (SPG) for the detection of GC and AG. Consequently, we conducted a systematic review and meta-analysis to assess the diagnostic accuracy of SPG in GC and AG detection.

Methods
We searched PubMed, Embase, and the Chinese National Knowledge Infrastructure (CNKI) for correlative original studies published up to September 30, 2014. The summary sensitivity, specificity, positive diagnostic likelihood ratio (DLR+), negative diagnostic likelihood ratio (DLR-), area under the summary receiver operating characteristic curve (AUC) and diagnostic odds ratio (DOR) were used to evaluate SPG in GC and AG screening based on bivariate random effects models. The inter-study heterogeneity was evaluated by the I² statistics and publication bias was assessed using Begg and Mazumdar’s test. Meta-regression and subgroup analyses were performed to explore study heterogeneity.

Results
In total, 31 studies involving 1,520 GC patients and 2,265 AG patients were included in the meta-analysis. The summary sensitivity, specificity, DLR+, DLR-, AUC and DOR for GC screening using SPG were 0.69 (95% CI: 0.60–0.76), 0.73 (95% CI: 0.62–0.82), 2.57 (95% CI: 1.82–3.62), and 0.43 (95% CI: 0.34–0.54), 0.76 (95% CI: 0.72–0.80) and 0.61 (95% CI: 3.69–9.79), respectively. For AG screening, the summary sensitivity, specificity, DLR+, DLR-, AUC and DOR were 0.69 (95% CI: 0.55–0.80), 0.88 (95% CI: 0.77–0.94), 5.80 (95% CI: 3.06–10.99), and 0.35 (95% CI: 0.24–0.51), 0.85 (95% CI: 0.82–0.88) and 16.50 (95%
CI: 8.18–33.28), respectively. In subgroup analysis, the use of combination of concentration of PGI and the ratio of PGI:PGII as measurement of SPG for GC screening yielded sensitivity of 0.70 (95% CI: 0.66–0.75), specificity of 0.79 (95% CI: 0.79–0.80), DOR of 6.92 (95% CI: 4.36–11.00), and AUC of 0.78 (95% CI: 0.72–0.81), while the use of concentration of PGI yielded sensitivity of 0.55 (95% CI: 0.51–0.60), specificity of 0.79 (95% CI: 0.76–0.82), DOR of 6.88 (95% CI: 2.30–20.60), and AUC of 0.77 (95% CI: 0.73–0.92). For AG screening, the use of ratio of PGI:PGII as measurement of SPG yielded sensitivity of 0.69 (95% CI: 0.52–0.83), specificity of 0.84 (95% CI: 0.68–0.93), DOR of 11.51 (95% CI: 6.14–21.56), and AUC of 0.83 (95% CI: 0.80–0.86), the use of combination of concentration of PGI and the ratio of PGI:PGII yield sensitivity of 0.79 (95% CI: 0.72–0.85), specificity of 0.89 (95% CI: 0.85–0.93), DOR of 24.64 (95% CI: 6.95–87.37), and AUC of 0.87 (95% CI: 0.81–0.92), concurrently, the use of concentration of PGI yield sensitivity of 0.46 (95% CI: 0.38–0.54), specificity of 0.93 (95% CI: 0.91–0.95), DOR of 19.86 (95% CI: 0.86–456.91), and AUC of 0.86 (95% CI: 0.52–1.00).

Conclusion

SPG has great potential as a noninvasive, population-based screening tool in GC and AG screening. In addition, given the potential publication bias and high heterogeneity of the included studies, further high quality studies are required in the future.

Introduction

Gastric cancer (GC) was the fifth most common cancer and the third leading cause of cancer-related mortality worldwide [1]. In the Asia-Pacific region, the incidence of GC is high in Japan, China, Korea, Singapore, and Malaysia and is low in Thailand, India, New Zealand and Australia[2]. The clinical symptoms in the early stages of GC are not specific; therefore, a large number of patients with early GC do not seek appropriate medical care until the disease has progressed [3], and the prognosis of patients with advanced GC remains poor [4]. GC develops in a stepwise manner, and subjects with precancerous lesions, such as atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia, may be at high risk of eventually developing carcinoma. Subsequently, it is important to improve the prognosis of GC by identifying its high-risk population. The development of tools for the early diagnosis of GC and precancerous lesions of GC is important for reducing mortality, increasing survival rates, and improving quality of life [5]. Endoscopy and biopsy are the reference standards for diagnosis and screening of GC and precancerous lesions of GC, but their use is limited for population-wide screening due to their invasiveness[6, 7]. Subsequently, it is necessary to identify novel, simple, cost-effective and manipulable screening methods for GC and precancerous lesions of GC.

Human pepsinogens are proenzymes for pepsin, a digestive enzyme produced by gastric chief cells. Human pepsinogens are biochemically and immunochemically classified into two groups: pepsinogen I (PGI) and pepsinogen II (PGII)[8, 9]. PGI is secreted by chief and mucous neck cells in the fundic glands, whereas PGII is also secreted by cells in the pyloric and Brunner’s glands[10]. PGI and II are secreted into the gastric lumen, and approximately 1% can be found in the serum. Serum pepsinogen (SPG) may function as a marker of the functional and morphologic status of the gastric mucosa, including atrophic changes and inflammation, such as H. pylori infection, AG and IM[11]. Serum PGI and PGII levels are increased.
with increasing severity of *H. pylori*-related chronic gastritis. However, when atrophic changes in the corpus are accompanied by a loss of cells in the corpus, including those secreting PGI, the level of PGI decreases, whereas the level of PGII remains high or stable. Therefore, the ratio of PGI:PGII decreases in a stepwise manner. More severe atrophy is related to a lower PGI: PGII ratio. The non-invasive markers PGI and PGII and their ratio have been proposed as predictors of various gastric pathologies, including AG and IM\[10, 12\], which are defined as precancerous lesions for GC\[13\]. In addition, several case-control and cohort studies have demonstrated the predictive value of SPG for GC diagnosis and screening, suggesting that it is possible to use SPG for GC screening on the basis of large populations. In Japan, SPG detection has become the first step of GC screening, instead of photofluorography\[14\].

SPG has been commonly accepted as a useful biomarker for GC screening and AG diagnosis, but its efficacy remains controversial. To obtain summary estimates of the diagnostic accuracy of SPG for screening GC and for the diagnosis of AG, the present meta-analysis was performed to assess the overall diagnostic performance of SPG in patients with GC or AG.

**Materials and methods**

**Search strategy**

Electronic searches were performed using PubMed, Embase, and the Chinese National Knowledge Infrastructure (CNKI). To assess the diagnostic value of SPG in GC, the following search terms were used: (1) (((((pepsinogen[Title/Abstract]) AND gastric cancer[Title/Abstract])) OR ((pepsinogen[Title/Abstract]) AND gastric carcinoma[Title/Abstract])) OR ((pepsinogen[Title/Abstract]) AND stomach carcinoma[Title/Abstract])) OR ((pepsinogen[Title/Abstract]) AND stomach cancer[Title/Abstract]) in PubMed and CNKI; (2) (TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(stomach cancer)) or (((TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(gastric cancer)) or (TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(gastric carcinoma))) in Embase (ScienceDirect). The search terms used for AG diagnosis by SPG were presented as follows: (1) (((gastritis[Title/Abstract]) AND pepsinogen[Title/Abstract]) OR ((intestinal metaplasia [Title/Abstract] AND pepsinogen[Title/Abstract])) OR ((dysplasia[Title/Abstract]) AND pepsinogen[Title/Abstract])) in PubMed and CNKI; (2) ((TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(gastritis)) or (TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(intestinal metaplasia)) or (TITLE-ABSTR-KEY(pepsinogen) and TITLE-ABSTR-KEY(dysplasia)) in Embase (ScienceDirect). The reference lists of all retrieved articles were reviewed to identify additional potentially relevant studies in adherence with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines.

**Selection criteria**

The studies included in the meta-analysis met the following criteria: (1) the studies or article abstracts were written in English or Chinese; (2) all GC, AG, IM or dysplasia patients were histologically confirmed by pathologists; (3) the studies detected serum or plasma pepsinogen in GC, AG, IM or dysplasia; (4) peripheral blood was collected for SPG detection before treatment; and (5) the study presented sensitivity, specificity, and clear cut-off values. If the articles contained the same or overlapping data, the largest or most recent populations were selected. Unqualified data, duplicate publications, case reports, conference abstracts, reviews, letters to journal editors, articles with no clear cut-off value, and small scale studies with fewer than 30 cases were excluded. The retrieved studies were evaluated, and relevant data from the included studies were extracted independently by two investigators (Y.K.H. and S.B.T.). Disagreement was resolved by discussion.
Data extraction and quality assessment of studies

The data extracted from studies included the following: (1) basic characteristics of studies, including: first author’s name; publication year; country of origin; the number of patients and controls; detection method; cut-off values; study design; pathological type and mean age; and (2) diagnostic performance, including sensitivity, specificity, TP, FP, FN, and TN. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) checklist was used by two reviewers (C.Y. and YK.H.) to assess study quality using RevMan 5.3[15]. However, studies were not excluded on the basis of quality. A proportional bar graph and summary table of review authors’ ratings for each criterion was plotted to characterize the results of our assessment.

Statistical analysis

We calculated the pooled sensitivity, pooled specificity, diagnostic odds ratio (DOR), positive diagnostic likelihood ratio (DLR+), negative diagnostic likelihood ratio (DLR-), and 95% confidence intervals (CIs) for each criterion. A summary receiver operator characteristic (SROC) curve was generated, and the area under the summary receiver operating characteristic curve (AUC) was calculated[16]. To assess the clinical utility of SPG for GC and AG diagnosis, Fagan’s nomograms were plotted. The threshold effect was assessed by Spearman’s correlation analysis. Heterogeneity was assessed using the $I^2$ statistics; $I^2 >50\%$ indicated moderate to high heterogeneity[17]. Meta-regression was performed to identify possible sources of heterogeneity. Subgroup analyses were also performed as necessary. Sensitivity analysis was performed to evaluate the effects of each individual study on the summary accuracy of SPG detection for GC and AG. A funnel plot followed by the Begg and Mazumdar’s test was used to explore potential publication bias. All analyses were performed with Stata 12.0 (College Station, TX, USA), Meta-DiSc statistical software[18], and RevMan 5.3 (Cochrane, USA).

Results

Identification of studies

For GC diagnosis, our initial database search retrieved 626 published articles, 90 of which were duplicates and were excluded. Among the remaining studies, 443 articles were not relevant to our research topic, 47 were meta-analyses or reviews, and 4 were comments or case-reports. Finally, 42 articles were subject to full-text analysis. One of these articles was excluded because the data could not be extracted, 1 were excluded because the studies did not present sensitivity, specificity, or clear cut-off values, 1 was excluded because of the combination of SPG and other serological markers, and 24 were excluded for not including a diagnostic accuracy test. Ultimately, 15 eligible articles were included in the present meta-analysis [6, 19–32](Fig 1A). For AG, IM or dysplasia diagnoses, our initial database search retrieved 718 published articles, 88 of which were duplicates and were excluded. Among the remaining studies, 523 articles did not meet the criteria, 49 were meta-analyses or reviews, and 15 were comments, letters or case-reports. Finally, 43 articles were subject to full-text analysis. Two of these articles were discarded because the data could not be extracted, 4 were discarded the studies did not present sensitivity, specificity, or clear cut-off values, 10 were discarded for having no correlation to the diagnostic accuracy test, 6 were discarded because of the combination of SPG and other serological markers, and 5 were discarded due to the application of SPG in GC diagnosis. Sixteen eligible articles were included in the present meta-analysis [12, 31, 33–46] (Fig 1B). No unpublished relevant studies were obtained.
Study characteristics and quality assessment

The characteristics of the included studies are summarized in Table 1. Briefly, the 31 studies represented 13 countries. In total, 27 studies were published in English, 2 were written in Chinese, and 1 was written in Korean. Overall, 1,520 GC patients and 27,723 control samples were included in 15 studies with respect to GC diagnosis. A total of 2,265 AG patients and 2,660 control samples were included in the 16 studies with respect to the diagnosis of AG. All patients were diagnosed by endoscopy and biopsy. The studies were published from 1991 to 2014 and used different detection methods and cut-off values, although most involved radio-immunity assays (RIA) and enzyme-linked immunosorbent assays (ELISA). The most commonly used cut-off values were PG I/C20 70 ng/ml and PG I:PG II/C20 3.0 (Table 1). Four articles contained different cut-off values within the same study, and we selected the cut-off values with the highest Youden’s index for the present analysis. For GC diagnosis, the sensitivity and specificity ranges were 37–91% and 36–97%, respectively, and the sensitivity and specificity ranges for the diagnosis of AG using SPG were 17–91% and 39–100%, respectively.

An assessment of the studies by QUADAS-2 is presented in Fig 2. The overall quality of the eligible studies for GC diagnosis was not robust, but the studies showed good overall quality with respect to the diagnosis of AG. The index test and reference standard did not have an interaction effect for any of the included studies. For GC diagnosis, 6 of the 15 included studies had a cohort design, and 9 were case-control studies. For AG diagnosis, 13 of the 16 included studies had a cohort design, and 3 were case-control studies. For GC diagnosis, all studies had strict reference standards, and 9 contained clearly defined inclusion and exclusion criteria. Three of the 15 included studies did not employ an appropriate interval between the reference standard and the index test, which potentially led to the introduction of bias. For the diagnosis of AG, all included studies also had strict reference standards and employed an appropriate interval between the reference standard and the index test; 10 contained clearly defined inclusion and exclusion criteria, and 6 did not.

Diagnostic accuracy of SPG in GC and AG

A forest plot was used to demonstrate the sensitivity, specificity, DLR+, and DLR- for the detection of SPG in GC screening and AG diagnosis. The I² values of the summary sensitivity, summary specificity, summary DLR+, and summary DLR- for studies of GC were 88.27% (95% CI: 83.46–93.07%), 99.61% (95% CI: 99.55–99.66%), 90.39% (95% CI: 90.39–95.41%), and 85.21% (95% CI: 78.74–91.68%), respectively. The I² values of the summary sensitivity,
Table 1. Characteristics of the studies included in the meta-analysis

| Author/year/region | Patients (n) | Control (n) | Cut-off | SPG detection method | Pathological type | TP (n) | FP (n) | FN (n) | TN (n) | Design | Mean age of patients (years)* |
|--------------------|--------------|-------------|---------|----------------------|------------------|--------|-------|-------|-------|--------|-----------------------------|
| F Kitahara, 1999, Japan[19] | 13 | 5,100 | PGI<70 ng/ml and PGI: PGII<3.0 | RIA | GC (cardia/non cardia: 1/12) | 11 | 1352 | 2 | 3,748 | Cohort | 52.3 |
| Abraham M. Y. Nomura, 2005, Hawaii[20] | 250 | 334 | PGI≤30 ng/ml | RIA | GC (cardia/non cardia: 29/221) | 96 | 65 | 154 | 169 | Case-control | 70.7 |
| Masahira Haneda, 2012, Japan[21] | 47 | 214 | PGI:PGII≤4.5 | CLIA | GC | 26 | 62 | 21 | 152 | Case-control | 57 |
| Ryousuke Kikuchi, 2011, Japan[22] | 122 | 179 | PGI<30 ng/ml and PGI: PGII<2.0 | CLIA | GC | 95 | 68 | 27 | 109 | Case-control | 68.2 |
| KENTARO SHIKATA, 2012, Japan[6] | 69 | 2,377 | PGI<59 ng/ml and PGI: PGII≤3.9 | CLIA | GC | 49 | 731 | 20 | 1,646 | Cohort | 57.3 |
| Rafael Lomba-Viana, 2012, Portugal[23] | 9 | 505 | PGI<70 ng/ml and PGI: PGII≤3.0 | ELISA | GC (cardia/non cardia: 0/9) | 6 | 268 | 3 | 237 | Cohort | 64 |
| Jung Mook Kang, 2008, South Korea[24] | 380 | 686 | PGI:PGII≤3.0 | L-TIA | GC | 225 | 268 | 155 | 418 | Case-control | 57.6 |
| Xiao-mei Zhang, 2014, China[25] | 82 | 142 | PGI<70 ng/ml | ELISA | GC | 56 | 25 | 26 | 117 | Case-control | NR |
| SHIGETO MIZUNO, 2009, Japan[26] | 19 | 12,101 | PGI<30 ng/ml and PGI: PGII≤2.0 | CLIA | GC (cardia/non cardia: 1/18) | 7 | 486 | 12 | 11,165 | Cohort | 57 |
| Yu-Yan Huang, 2013, China[27] | 55 | 211 | PGI<73.14 ng/ml | ELISA | GC | 50 | 58 | 5 | 153 | Case-control | 60 |
| Zhong-Lin Yu, 2008, China[28] | 148 | 2,520 | PGI<70 ng/ml and PGI: PGII≤3.0 | ELISA | GC | 28 | 96 | 27 | 443 | Cohort | NR |
| Metin Agkoc, 2010, Turkey[31] | 50 | 30 | PGI<25 ng/ml and PGI: PGII≤3.0 | RIA | GC | 41 | 1 | 9 | 29 | Case-control | 65.42 |
| Masaharu Yoshihara, 1998, Japan[29] | 25 | 3157 | PGI<50 ng/ml and PGI: PGII≤3.0 | RIA | GC | 21 | 2028 | 4 | 1129 | Cohort | Null |
| F.-Y. CHANG, 1992, Taiwan[30] | 192 | 70 | PGI<70 ng/ml | RIA | GC | 124 | 12 | 68 | 58 | Case-control | Null |
| Kazuo Aoki, 1997, Japan[32] | 59 | 97 | PG I<40 ng/ml and PG I:PG II<3.0 | RIA | GC | 38 | 13 | 21 | 84 | Case-control | 64 |
| A. Oksanen, 2000, Finland[33] | 90 | 54 | PGI<84.4 ng/ml | ELISA | AG | 15 | 0 | 75 | 54 | Cohort | 55 |
| Cai-yun He, 2011, China[34] | 1,556 | 466 | PGIIFF1E<8.25 ng/ml | ELISA | AG | 1099 | 136 | 457 | 330 | Cohort | 53.16 |
| Diana Aulia, 2009, Indonesia[35] | 26 | 37 | PGI<119 ng/ml | ELISA | AG | 18 | 18 | 8 | 19 | Case-control | 47.6 |
| Metin Agkoc, 2010, Turkey[31] | 30 | 30 | PGI<25 ng/ml and PGI: PGII<3.0 | RIA | AG | 27 | 0 | 3 | 30 | Case-control | 32.86 |

(Continued)
summary specificity, summary DLR+, and summary DLR- for studies of AG were 93.67% (95% CI: 91.58–95.76%), 97.57% (95% CI: 96.98–98.17%), 93.82% (95% CI: 93.82–96.69%), and 96.57% (95% CI: 95.63–97.51%), respectively. The results indicated high heterogeneity in the sampled studies. Therefore, a random-effects model was performed. The resulting summary sensitivity, summary specificity, summary DLR+, and summary DLR- for studies of GC were 0.69 (95% CI: 0.60–0.76), 0.73 (95% CI: 0.62–0.82), 2.57 (95% CI: 1.82–3.62), and 0.43 (95% CI: 0.34–0.54) (Fig 3), respectively. The resulting summary sensitivity, summary specificity, summary DLR+, and summary DLR- for studies of AG were 0.69 (95% CI: 0.55–0.80), 0.88 (95% CI: 0.77–0.94), 5.80 (95% CI: 3.06–10.99), and 0.35 (95% CI: 0.24–0.51) (Fig 4), respectively. The SROC graphs with a 95% confidence region and a 95% prediction region are presented in Fig 5 and the forest plots of DOR are presented in Fig 6. For GC, the AUC was 0.76 (95% CI: 0.72–0.80), and the DOR was 6.01 (95% CI: 3.69–9.79). For AG, the AUC was 0.85 (95% CI: 0.82–0.88), and the DOR was 16.50 (95% CI: 8.18–33.28). In our study, we performed Spearman’s correlation analysis to explore possible threshold effects. Spearman’s correlation coefficient for GC was 0.486 (P = 0.066), and Spearman’s correlation coefficient for AG was

Table 1. (Continued)

| Author/year/region | Patients (n) | Control (n) | Cut-off SPG detection method | Pathological type | TP (n) | FP (n) | FN (n) | TN (n) | Design | Mean age of patients (years)* |
|---------------------|--------------|-------------|-------------------------------|------------------|--------|-------|-------|-------|--------|-----------------------------|
| Katsunori Iijima, 2009, Japan [36] | 20 | 142 | PGI<70 ng/ml and PGI: PGII<2.0 | ELISA | AG | 9 | 6 | 11 | 136 | Cohort | 55 |
| Hyoijn Chae, 2008, Korea [37] | 59 | 67 | PGI:PGII<4.0 | L-TIA | AG | 49 | 6 | 10 | 61 | Cohort | 50.8 |
| R. Sierra, 2006, Costa Rica [38] | 34 | 400 | PGI:PGII<3.4 | ELISA | AG | 31 | 246 | 3 | 154 | Cohort | 46 |
| Ma’rio Dinis-Ribeiro, 2004, Portugal [39] | 61 | 74 | PGI:PGII<3.05 | ELISA | AG with IM | 40 | 16 | 21 | 58 | Cohort | 61 |
| Kai Chun WU, 2004, China [40] | 27 | 54 | PGI:PGII<8.1 | ELISA | AG | 24 | 9 | 3 | 45 | Cohort | 64.8 |
| N Broutet, 2003, Finland [41] | 62 | 222 | PGI:PGII<5.6 | RIA | AG | 40 | 49 | 22 | 173 | Cohort | 43.5 |
| Abbas Zoalfaghari, 2013, Iran [42] | 51 | 59 | PGI:PGII<4.0 | ELISA | AG | 36 | 17 | 15 | 42 | Cohort | 51.4 |
| David Y Graham, 2006 Mexico [12] | 5 | 122 | PGI:PGII<6.7 | ELISA | AG | 4 | 35 | 1 | 87 | Cohort | NR |
| M. Kekki, 1991, Finland [43] | 46 | 654 | PGI<30 ng/ml | RIA | AG | 41 | 34 | 5 | 620 | Cohort | 47 |
| G. Nardone, 2005, Italy [44] | 30 | 64 | PGI:PGII<3.0 | ELISA | AG | 9 | 0 | 21 | 64 | Cohort | 56 |
| Manami Inoue, 1998, Japan [45] | 117 | 83 | PGI<70 ng/ml and PGI: PGII<3.0 | RIA | AG | 96 | 21 | 21 | 62 | Cohort | 60.5 |
| F. Sitas, Netherlands, 1993 [46] | 28 | 33 | PGI:PGII<1.5 | ELISA | AG | 7 | 2 | 21 | 31 | Case-control | 47.4 |

Note: RIA, radio-immunity assay; ELISA, enzyme-linked immunosorbent assay; CLIA, chemiluminescent immunoassay; L-TIA, latex-enhanced turbidimetric immunoassay; NR, no report.

*mean age of patients; GC, gastric cancer; AG, atrophic gastritis; IM, intestinal metaplasia.

doi:10.1371/journal.pone.0142080.t001
0.362 (P = 0.169), indicating no threshold effects. To assess the clinical utility of the index test, a Fagan’s nomogram was generated to compare the prior and posterior probabilities (Fig 7). For GC, when a prior probability of 20% was specified, the posterior probability positivity increased to 39%, with a DLR+ of 3.00. In addition, the posterior probability negativity decreased to 10.00%, with a DLR- of 0.43. A similar result was observed in AG diagnosis: when a prior probability of 20% was specified, the posterior probability positivity increased to 59%, with a DLR+ of 6.00, and the posterior probability negativity decreased to 8.00%, with a DLR- of 0.35. These findings suggest a moderate value for SPG in the diagnosis of GC and AG.

Meta-regression and subgroup analysis
To explore the potential sources of inter-study heterogeneity, a meta-regression was performed for both GC and AG. The results indicated that the scale of the included patients could represent a potential source of heterogeneity for GC diagnosis (P = 0.0080), whereas the study design (P = 0.0295), SPG detection method (P = 0.0343) and measurement of SPG (P = 0.0334) were the major sources of heterogeneity for the SPG assay in AG detection. Consequently, we performed subgroup analyses, as shown in Table 2 and Table 3. For GC, the results indicated
that studies with less than 50 patients exhibited an increased diagnostic accuracy of SPG detection compared with studies with greater than 50 patients. Similar findings were obtained in subgroups with the following characteristics: the use of ELISA method, the use of combination of concentration of PGI and the ratio of PGI:PGII as measurement of SPG, studies with appropriate interval between standard and index test, case-control design and studies not containing clearly defined inclusion and exclusion criteria. A latex-enhanced turbidimetric immunoassay (L-TIA) was commonly used to quantify serum proteins[47], and Huang M et al. established the use of reference intervals (RIs) for SPG in a healthy Chinese population using L-TIA[48]. We did not identify a sufficient number of studies to evaluate the diagnostic accuracy of the L-TIA test; therefore, we did not include the L-TIA in our subgroup analysis for GC. For AG, the diagnostic accuracy of SPG testing was higher in studies using combination of concentration of PGI and the ratio of PGI:PGII as the measurement of SPG than in studies with other
measurements of SPG. Similar findings were also found in studies with cohort design, unclearly defined inclusion and exclusion criteria and the use of RIA method. The summary diagnostic accuracies of studies with the use of L-TIA method or concentration of PGII as measurement of SPG were not calculated because of an insufficient number of studies.

Sensitivity analysis

We performed a sensitivity analysis to evaluate the effects of each individual study on the summary accuracy of SPG detection for GC and AG, as shown in Table 4 and Table 5. After each study was separately removed, the summary sensitivity, specificity, DOR and AUC ranges with 95% CIs were calculated. We found a relatively stable diagnostic accuracy of SPG detection for GC and AG in each group.
Fig 5. Summary ROC curve (SROC) with 95% confidence region and 95% prediction region. (a) SROC for SPG in the diagnosis of GC; (b) SROC for SPG in the diagnosis of AG.

doi:10.1371/journal.pone.0142080.g005
Fig 6. Forest plots of DOR for SPG detection in GC and AG. (a) For GC detection, the DOR was 6.01 (95% CI: 3.69–9.79); (b) For AG detection, the DOR was 16.50 (95% CI: 8.18–33.28).

doi:10.1371/journal.pone.0142080.g006
Publication bias

To analyze the publication bias of the included studies, Begg’s funnel plot was constructed. As shown in Fig 8, the P value was 0.002 for GC and <0.001 for AG, indicating potential publication bias among the studies.

Discussion

GC was the world’s third leading cause of cancer mortality in 2012 and was responsible for 723,100 deaths [49, 50]. Korea, Japan, and China are among the areas with increased risk of GC[51]. Despite the decreased incidence rate of GC observed around the world, its prognosis remains poor. To effectively improve the survival rate of GC, improved large-scale screening tools for earlier diagnosis of GC and the identification of people at high risk for GC must be developed. Precancerous lesions of GC include AG, IM, and dysplasia, and it has been estimated that 0%–1.8%, 0%–10%, and 0%–73% of patients with AG, IM, and dysplasia, respectively, progress to GC annually[52]. Several noninvasive tests, including photofluorography,
Table 2. Subgroup analysis of the included studies for GC.

| Subgroup | N  | Sensitivity (95% CI) | Specificity (95% CI) | DOR (95% CI) | AUC (95% CI) |
|----------|----|---------------------|----------------------|--------------|-------------|
| Patient scale | | | | | |
| ≤50 subjects | 6  | 0.71 (0.64–0.78) | 0.80 (0.80–0.81) | 8.27 (5.06–13.51) | 0.79 (0.69–0.88) |
| ≥50 subjects | 9  | 0.60 (0.57–0.63) | 0.71 (0.70–0.72) | 5.65 (3.48–9.17) | 0.75 (0.68–0.79) |
| Detection method | | | | | |
| RIA | 7  | 0.58 (0.54–0.62) | 0.62 (0.61–0.63) | 7.32 (3.74–14.33) | 0.80 (0.69–0.89) |
| ELISA | 3  | 0.73 (0.65–0.80) | 0.61 (0.58–0.64) | 11.99 (2.71–52.96) | 0.84 (0.73–0.95) |
| CLIA | 3  | 0.70 (0.63–0.77) | 0.95 (0.95–0.96) | 7.24 (4.50–11.65) | 0.78 (0.75–0.80) |
| L-TIA | 2  | Null | Null | Null | Null |
| Measurement of SPG | | | | | |
| Combination of concentration of PGI and the ratio of PGI:PGII | 9  | 0.70 (0.66–0.75) | 0.79 (0.79–0.80) | 6.92 (4.36–11.00) | 0.78 (0.72–0.81) |
| Ratio of PGI:PGII | 2  | Null | Null | Null | Null |
| Concentration of PGI | 4  | 0.55 (0.51–0.60) | 0.79 (0.76–0.82) | 6.88 (2.30–20.60) | 0.77 (0.73–0.92) |
| Interval between standard and index test | | | | | |
| appropriate interval | 12 | 0.61 (0.58–0.64) | 0.62 (0.61–0.63) | 6.53 (4.02–10.62) | 0.77 (0.71–0.83) |
| Inappropriate interval | 3  | 0.51 (0.42–0.57) | 0.90 (0.90–0.91) | 5.73 (2.23–14.76) | 0.75 (0.68–0.81) |
| Study design | | | | | |
| Cohort | 6  | 0.64 (0.57–0.71) | 0.79 (0.79–0.80) | 5.54 (3.35–9.18) | 0.74 (0.70–0.79) |
| Case-control | 9  | 0.61 (0.58–0.63) | 0.71 (0.69–0.73) | 7.04 (3.90–12.69) | 0.77 (0.68–0.86) |
| Clearly defined inclusion and exclusion criteria | | | | | |
| Yes | 9  | 0.60 (0.57–0.63) | 0.89 (0.89–0.90) | 5.96 (3.59–9.88) | 0.75 (0.68–0.82) |
| No | 6  | 0.69 (0.62–0.75) | 0.60 (0.59–0.61) | 7.36 (3.20–16.93) | 0.79 (0.68–0.90) |

Note: AUC, area under the summary receiver operating characteristic curve; DOR, diagnostic odds ratio; RIA, radio-immunity assay; ELISA, enzyme-linked immunosorbent assay; CLIA, chemiluminescent immunoassay; L-TIA, latex-enhanced turbidimetric immunoassay; CI, confidence interval

doi:10.1371/journal.pone.0142080.t002

Serum Pepsinogens in Gastric Cancer and Atrophic Gastritis Screening

Serum levels of PGI and PGII and *H. pylori* serology, are performed to screen for GC or precancerous lesions of GC. However, photofluorography has several disadvantages, such as X-ray exposure for individuals who are screened and low sensitivity in detecting early GC [10]. *H. pylori* serology is also not advantageous as a single screening modality because of its low specificity in distinguishing precancerous lesions [53]. SPG is a biomarker used to identify AG, and its potential utility in the diagnosis of GC has been demonstrated by numerous studies. Subsequently, cancer screening programs in Japan have accepted the measurement of SPG as a noninvasive screening test of GC. The measurement of SPG may detect AG or IM in a noninvasive manner, which is helpful to reduce the related morbidity and mortality of GC. In addition, the cost for the detection of a single cancer case by SPG is much less than that for conventional screening ($37,360 by conventional screening vs. $19,282 by SPG testing)[14]. However, only a
Table 3. Subgroup analysis of the included studies for AG.

| Subgroup                                            | N  | Sensitivity (95% CI) | Specificity (95% CI) | DOR (95% CI) | AUC (95% CI) |
|-----------------------------------------------------|----|----------------------|----------------------|--------------|--------------|
| Measurement of SPG                                  |    |                      |                      |              |              |
| Ratio of PGI:PGII                                   | 9  | 0.69 (0.52–0.83)     | 0.84 (0.68–0.93)     | 11.51 (6.14–21.56) | 0.83 (0.80–0.86) |
| Combination of concentration of PGI and the ratio of PGI:PGII | 3  | 0.79 (0.72–0.85)     | 0.89 (0.85–0.93)     | 24.64 (6.95–87.37) | 0.87 (0.81–0.92) |
| Concentration of PGI                                | 3  | 0.46 (0.38–0.54)     | 0.93 (0.91–0.95)     | 19.86 (0.86–456.91) | 0.86 (0.52–1.00) |
| Concentration of PGII                               | 1  | Null                 | Null                 | Null         | Null         |
| Detection method                                    |    |                      |                      |              |              |
| ELISA                                               | 11 | 0.67 (0.65–0.69)     | 0.68 (0.65–0.70)     | 7.51 (4.96–11.37) | 0.77 (0.75–0.80) |
| RIA                                                 | 4  | 0.80 (0.75–0.85)     | 0.89 (0.87–0.91)     | 35.01 (7.31–167.66) | 0.86 (0.69–0.96) |
| L-TIA                                               | 1  | Null                 | Null                 | Null         | Null         |
| Study design                                        |    |                      |                      |              |              |
| Cohort                                              | 13 | 0.69 (0.67–0.71)     | 0.77 (0.75–0.78)     | 14.69 (8.33–25.91) | 0.85 (0.80–0.91) |
| Case-control                                        | 3  | 0.62 (0.51–0.71)     | 0.80 (0.71–0.87)     | 12.40 (1.02–150.57) | 0.82 (0.52–1.00) |
| Clearly defined inclusion and exclusion criteria     |    |                      |                      |              |              |
| Yes                                                 | 10 | 0.69 (0.64–0.73)     | 0.67 (0.64–0.70)     | 8.77 (5.35–14.38) | 0.81 (0.75–0.87) |
| No                                                  | 6  | 0.69 (0.67–0.71)     | 0.86 (0.84–0.88)     | 30.35 (8.12–113.43) | 0.90 (0.79–0.96) |

Note: AUC, area under the summary receiver operating characteristic curve; DOR, diagnostic odds ratio; RIA, radio-immunity assay; ELISA, enzyme-linked immunosorbent assay; L-TIA, latex-enhanced turbidimetric immunoassay; CI, confidence interval

doi:10.1371/journal.pone.0142080.003

Table 4. Sensitivity analyses for the diagnostic accuracy of SPG for GC.

| Study omitted           | Sensitivity (95% CI) | Specificity (95% CI) | DOR (95% CI) | AUC (95% CI) |
|------------------------|----------------------|----------------------|--------------|--------------|
| F Kitahara, 1999       | 0.68 (0.59–0.76)     | 0.73 (0.61–0.83)     | 5.80 (3.48–9.68) | 0.75 (0.71–0.79) |
| Abraham M. Y. Nomura, 2005 | 0.71 (0.63–0.78)   | 0.71 (0.58–0.82)     | 6.16 (3.61–10.49) | 0.77 (0.73–0.80) |
| Masahira Haneda, 2012  | 0.70 (0.61–0.77)     | 0.74 (0.61–0.83)     | 6.33 (3.79–10.69) | 0.77 (0.73–0.80) |
| Ryousuke kikuchi, 2011 | 0.68 (0.59–0.76)     | 0.74 (0.60–0.83)     | 6.05 (3.55–10.30) | 0.76 (0.72–0.79) |
| KENTARO SHIKATA, 2012 | 0.69 (0.60–0.77)     | 0.74 (0.62–0.83)     | 6.11 (3.59–10.38) | 0.76 (0.72–0.80) |
| Rafael Lomba-Viana, 2012 | 0.69 (0.60–0.76)   | 0.75 (0.64–0.84)     | 6.48 (3.95–10.62) | 0.77 (0.73–0.80) |
| Jung Mook Kang, 2008   | 0.70 (0.61–0.78)     | 0.74 (0.62–0.83)     | 6.59 (4.01–10.83) | 0.77 (0.73–0.81) |
| Xiao-mei Zhang, 2014   | 0.69 (0.60–0.77)     | 0.71 (0.60–0.80)     | 5.39 (3.41–8.52)  | 0.75 (0.71–0.79) |
| SHIGETO MIZUNO, 2009   | 0.69 (0.60–0.77)     | 0.72 (0.60–0.82)     | 5.71 (3.49–9.47)  | 0.76 (0.72–0.79) |
| Yu-Yan Huang, 2013     | 0.66 (0.58–0.73)     | 0.76 (0.66–0.84)     | 6.12 (3.62–10.33) | 0.75 (0.71–0.79) |
| Zhong-Lin Yu, 2008     | 0.70 (0.61–0.77)     | 0.73 (0.60–0.82)     | 6.16 (3.63–10.56) | 0.77 (0.73–0.80) |
| Masaharu Yoshihara, 1998 | 0.67 (0.59–0.75)   | 0.76 (0.65–0.84)     | 6.38 (3.85–10.58) | 0.76 (0.73–0.80) |
| F.-Y. CHANG, 1992      | 0.69 (0.60–0.77)     | 0.73 (0.60–0.82)     | 5.91 (3.50–9.96)  | 0.76 (0.72–0.80) |
| Metin Agkoc, 2010      | 0.68 (0.58–0.75)     | 0.71 (0.60–0.80)     | 5.15 (3.40–7.79)  | 0.74 (0.70–0.78) |
| Kazuo Aoki, 1997       | 0.69 (0.60–0.77)     | 0.72 (0.60–0.82)     | 5.77 (3.46–9.62)  | 0.76 (0.72–0.79) |

Note: AUC, area under the summary receiver operating characteristic curve; DOR, diagnostic odds ratio; CI, confidence interval

doi:10.1371/journal.pone.0142080.004
few meta-analyses on the accuracy of SPG for predicting GC or precancerous lesions of GC are available. Our study performed a meta-analysis to clarify the diagnostic value of SPG.

The present study, including a total of 3,785 patients, identified a moderate capacity for SPG to detect GC and AG; the summary sensitivity and summary specificity for GC diagnosis were 0.69 (95% CI: 0.60–0.76) and 0.73 (95% CI: 0.62–0.82), respectively. Concurrently, the summary sensitivity and summary specificity for AG diagnosis were 0.69 (95% CI: 0.60–0.76) and 0.88 (95% CI: 0.77–0.94), respectively. The AUC values were calculated to evaluate the discriminating ability of this diagnostic method[54]. DOR combines sensitivity and specificity to assess diagnostic accuracy. The AUC and DOR of the SPG test for GC diagnosis were 0.76 (95% CI: 0.72–0.80) and 0.88 (95% CI: 0.77–0.94), respectively. For AG, the AUC and DOR were 0.85 (95% CI: 0.82–0.88) and 16.50 (95% CI: 8.18–33.28), respectively. A Fagan plot indicated that the use of SPG could moderately improve the GC and AG detection rate, confirming a moderate efficiency of SPG detection in GC and AG diagnosis. Nevertheless, we believe that SPG detection has a potentially significant role in GC mass screening, especially in the identification of populations at high risk for GC[25]. The study conducted by Jennifer M Yeh and colleagues suggested that targeting high-risk smokers for SPG screening might be a cost-effective strategy to reduce intestinal-type non-cardia GC mortality[55]. If combined with an additional GC screening method, such as serum MG7-Ag, serum gastrin-17, serum ghrelin and serum trefoil factor family 3 (TFF-3), the efficiency of GC screening could be improved. The combination of serum IgG anti- *H. pylori* antibody, gastrin, PG I and PG II was identified to be useful for predicting the presence of GC[56]. Susumu Aikou et al demonstrated that serum TFF-3 could be an effective marker of GC with sensitivity of 80.9% and specificity of 81.0%, while the combination of serum TFF-3 and SPG statistical significantly improved tumor detection as compared to TFF3 or SPG alone[57]. Zhigang Huang and colleagues also suggested that the combined testing of serum TFF-3 and SPG could further improve the efficacy of GC screening[58]. In addition, Combinations of SPG, gastrin-17 and *H. pylori* antibody can also identify AG more effectively[59, 60]. The plasma levels of ghrelin was indicated to be correlated well with

### Table 5. Sensitivity analyses for the diagnostic accuracy of SPG for AG.

| Study omitted                      | Sensitivity (95% CI) | Specificity (95% CI) | DOR (95% CI) | AUC (95% CI) |
|-----------------------------------|----------------------|----------------------|--------------|--------------|
| Manami Inoue, 1998                | 0.68 (0.53–0.80)     | 0.90 (0.77–0.95)     | 17.00 (7.88–36.70) | 0.85 (0.82–0.88) |
| F. Sitas, 1993                    | 0.72 (0.59–0.82)     | 0.88 (0.75–0.95)     | 17.89 (8.47–37.79) | 0.86 (0.82–0.88) |
| A. Oksanen, 2000                  | 0.73 (0.61–0.82)     | 0.86 (0.74–0.92)     | 15.94 (7.70–31.37) | 0.85 (0.82–0.88) |
| Cai-yun He, 2011                  | 0.69 (0.54–0.81)     | 0.89 (0.77–0.95)     | 18.27 (8.61–38.76) | 0.86 (0.83–0.89) |
| Diana Aulia, 2009                 | 0.69 (0.54–0.81)     | 0.89 (0.79–0.95)     | 18.68 (9.26–37.69) | 0.87 (0.83–0.89) |
| Metin Agkoc, 2010                 | 0.67 (0.53–0.79)     | 0.87 (0.75–0.94)     | 13.56 (7.33–25.08) | 0.84 (0.80–0.87) |
| Katsunori Iijima, 2009            | 0.71 (0.56–0.82)     | 0.87 (0.74–0.94)     | 16.42 (7.70–35.03) | 0.86 (0.82–0.88) |
| Hyojin Chae, 2008                 | 0.68 (0.53–0.80)     | 0.88 (0.75–0.95)     | 15.25 (7.36–31.61) | 0.85 (0.81–0.87) |
| R. Sierra, 2006                   | 0.67 (0.53–0.78)     | 0.90 (0.80–0.95)     | 17.32 (8.31–36.12) | 0.86 (0.83–0.89) |
| Mário Dinis-Ribeiro, 2004         | 0.69 (0.55–0.81)     | 0.89 (0.77–0.95)     | 18.00 (8.42–38.47) | 0.86 (0.83–0.89) |
| Kai Chun WU, 2004                 | 0.67 (0.53–0.79)     | 0.89 (0.76–0.95)     | 15.88 (7.32–33.52) | 0.84 (0.81–0.87) |
| N Broutet, 2003                   | 0.70 (0.55–0.81)     | 0.89 (0.77–0.95)     | 18.17 (8.52–38.76) | 0.86 (0.83–0.89) |
| Abbas Zoalfaghari, 2013           | 0.69 (0.54–0.81)     | 0.89 (0.77–0.95)     | 18.07 (8.51–38.34) | 0.86 (0.83–0.89) |
| David Y Graham, 2006              | 0.68 (0.54–0.80)     | 0.89 (0.77–0.95)     | 17.43 (8.24–36.86) | 0.86 (0.82–0.88) |
| M. Kekki, 1991                    | 0.67 (0.53–0.79)     | 0.87 (0.74–0.94)     | 13.55 (7.14–25.74) | 0.84 (0.80–0.86) |
| G. Nardone, 2005                  | 0.71 (0.58–0.82)     | 0.86 (0.74–0.92)     | 14.75 (7.39–29.46) | 0.85 (0.82–0.88) |

Note: AUC, area under the summary receiver operating characteristic curve; DOR, diagnostic odds ratio; CI, confidence interval.
Fig 8. Begg’s funnel plot was constructed to demonstrate publication bias. (a) Begg’s funnel plot for GC; (b) Begg’s funnel plot for AG.

doi:10.1371/journal.pone.0142080.g008
the serum levels of PGI as well as the PGI/II ratio in AG patients, suggesting that it could be an
intriguing non-invasive marker for AG[61]. Inverse associations between ghrelin and GC was
observed, suggesting a potential role for serum ghrelin as a biomarker of GC [62]. Based on the
rapidly growing research area of proteomics, promising serum GC and AG biomarkers will
hopefully be developed in the near future[63]. These studies may provoke more detailed inves-
tigations leading to identification of a panel of diagnostic serological markers applicable to GC
surveillance programmes.

Substantial heterogeneity was noted in the interpretation of the results of the 11 included
studies for GC: (1) Potential sources of heterogeneity derived from the different scales used for
the patients were explored by meta-regression. Some studies focused on the screening value of
SPG detection for GC, leading to the inclusion of fewer patients and more controls, whereas
others focused on confirming the diagnostic value of SPG detection. Studies with smaller num-
bers of patients may have found a lower reliability of SPG as a diagnostic test. (2) 3 studies did
not exhibit an appropriate interval between the reference standard and the index test. In this
setting, if SPG was detected long before endoscopy, the patient's condition would progress. If
patients with positive SPG detection received special treatment before undergoing endoscopy
and biopsy, this condition might have interfered with the diagnostic test results. The unclear
interval between SPG detection and endoscopic biopsy potentially constitutes a source of het-
erogeneity. (3) Two of the 15 included studies exclusively enrolled early GC patients, and the
SPG concentrations of early GC patients might differ from those of advanced GC patients, thus
constituting another potential source of heterogeneity. (4) Seven of the 15 included studies
used RIA to detect SPG, 3 used ELISA, 3 used CLIA, and only 2 used L-TIA. These different
detection methods could have generated different normal ranges and cut-off values of SPG.
Although the present study indicated that SPG detection using ELISA exhibited an increased
diagnostic accuracy, this difference might induce potential heterogeneity. For AG diagnosis,
the study design, SPG detection method and measurement of SPG constitute significant
sources of heterogeneity among the studies. Thirteen of 16 studies had cohort design, whereas
3 had case-control design. The different study designs may influence the diagnostic accuracy.
Eleven of the 16 studies used ELISA to detect SPG, whereas 4 used RIA, and 1 used L-TIA. An
excellent correlation was observed between ELISA and RIA for SPG detection[64], but the dif-
ferent methods yielded different cut-off values, which led to different diagnostic accuracies.
Nine studies used the ratio of PGI:PGII as the measurement of SPG, 3 used both the concentra-
tion of PGI and the ratio of PGI:PGII, 3 used the concentration of PGI, and 1 used the concen-
tration of PGII. PGI<70 ng/ml and PGII<3.0 are widely accepted as the cut-off points for
GC screening in Japan[19], but the ratio of PGI:PGII has mostly been used in AG diagnosis.

Several potential limitations of the present study must be acknowledged. First, although a
serum PGI concentration of<70 ng/ml and a PGI:II ratio of<3.0 have been widely accepted as
the cut-off points in Japan, the included studies employed various SPG cut-off values and dif-
ferent SPG analytical technologies, and different studies exhibited different sensitivities and
specificities. Despite this variation, we performed subgroup analyses and plotted the SROC
curves to counteract the influence of various analytical technologies and different cut-off val-
ues; however, the potential for residual influence on the accuracy of the summary diagnostic
parameters remains. Second, GC has different subtypes and different tumor sites, such as the
intestinal and diffuse types as well as cardia and non-cardia carcinoma. Intestinal-type GC has
no link to AG, so serological markers of gastric mucosal changes are minimal, but those
changes are obvious in diffuse-type GC. Gastric cardia and non-cardia cancer are also different
eaetiologically, cardia cancers are made up from two distinct aetiologies, one related to H.pylori
and AG (similar to non-cardia cancer), and the other related to gastro-oesophageal reflux dis-

Serum Pepsinogens in Gastric Cancer and Atrophic Gastritis Screening
be different from patients with gastric non-cardia cancer. Due to the absence of sufficient data about subtypes of GC, the assessment of diagnostic value of SPG for GC detection is limited. In addition, serum levels of PGI and the ratio of PGI:II decreased more significantly in AG patients with IM than in AG patients without IM. H. pylori infection status can also affect the concentration of SPG in AG patients and GC patients. These unrecorded differences in the patients of the selected studies potentially contributed to the observed heterogeneity[65].

Because these details were not available, our ability to explore the source of heterogeneity was restricted. However, a more homogeneous analysis may have resulted in selection bias. Third, potential publication bias was observed among the included studies, suggesting that the diagnostic value of SPG in both GC and AG detection may be overestimated because of selective reporting. Studies with favorable results are more likely to be published. Fourth, some of the studies had a case-control design, which may be prone to overrating the accuracy of a diagnostic trial [66]. Fifth, even though increasing the detection rate of early GC could improve the overall prognosis[67], only 2 studies in the present analysis focused on the early detection of GC. There is a great need to conduct clinical trials to better identify the validity of SPG in the early detection of GC in the future. Sixth, most of the included studies for GC were based in Asian countries; only two eligible studies originated in Europe. This geographically limited distribution could also introduce sampling bias in GC diagnosis. It remains urgent to validate whether the value of SPG detection for GC screening applies to different populations worldwide.

In conclusion, SPG has the potential to play an important role in the identification of patients with AG, which are precancerous lesions of GC. SPG also constitutes a crucial component in GC screening for the susceptible population, although this biomarker only exhibits a moderate diagnostic value for identifying GC. Given the limitations and heterogeneity of the chosen studies, large-scale and well-designed prospective studies should be conducted to validate the clinical value of SPG in GC screening and the diagnosis of precancerous lesions of GC (AG, IM and dysplasia), especially in European and American

**Supporting Information**

S1 Checklist. PRISMA 2009 Checklist. (DOC)

S2 Checklist. QUADAS-2 Checklist. (PDF)

**Author Contributions**

Conceived and designed the experiments: J-CY. Performed the experiments: Y-KH. Analyzed the data: Y-KH S-BT CY. Contributed reagents/materials/analysis tools: W-MK Z-QM XY. Wrote the paper: Y-KH.

**References**

1. Wang K, Liang Q, Li X, Tsoi H, Zhang J, Wang H, et al. MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome. Gut. 2015. doi: 10.1136/ gutjnl-2015-309276 PMID: 26206665

2. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2004; 7(1):9–16. doi: 10.1007/s10120-003-0265-0 PMID: 15092434

3. Liu D, Zhang L, Shen Z, Tan F, Hu Y, Yu J, et al. Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and
4. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206–1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(12):2282–7. doi:10.1200/JCO.2003.06.103 PMID: 12805327

5. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World journal of gastroenterology: WJG. 2014; 20(38):13842–62. doi:10.3748/wjg.v20.i38.13842 PMID: 25320521; PubMed Central PMCID: PMC4194567

6. Shikata K, Ninomiya T, Yonemoto K, Ikeda F, Hata J, Doi Y, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scandinavian journal of gastroenterology. 2012; 47(6):669–75. doi: 10.3109/00365521.2012.658855 PMID: 22428879

7. Choi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc. 2014; 47(6):497–503. doi:10.5946/ce.2014.47.6.497 PMID: 25505714; PubMed Central PMCID: PMC4260096

8. Samloff IM. Immunologic studies of human group I pepsinogens. Journal of immunology. 1971; 106(4):962–8. PMID:4396533

9. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Shakeri R, Persson EC, Islami F, et al. Accuracy and cutoff values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PloS one. 2011; 6(10):e26957. doi:10.1371/journal.pone.0026957 PMID: 22066020; PubMed Central PMCID: PMC3204997

10. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007; 8(1):8–14. doi:10.1111/j.1443-9573.2007.00278.x PMID: WOS:000256831800002

11. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982; 83(1 Pt 2):204–9. Epub 1982/07/01. PMID:7084603

12. Graham DY, Nurgalieva ZZ, El-Zimaity HM, Opekun AR, Campos A, Guerrero L, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006; 4(3):306–14. doi:10.1016/j.cgh.2005.11.003 PMID: 16527893

13. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52(24):6735–40. PMID:1458460

14. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007; 46(6):261–6. PMID:17379991

15. Zeng Z, Fu S, Hu P, Zhao L, Zhang H, Tang X, et al. The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis. Clinical and experimental medicine. 2014; 14(3):337–43. doi:10.1007/s10238-013-0246-5 PMID:23979567

16. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC medical research methodology. 2011; 11:41. doi:10.1186/1471-2288-11-41 PMID:21473747; PubMed Central PMCID: PMC3102034

17. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC medical research methodology. 2006; 6:31. doi:10.1186/1471-2288-6-31 PMID: 16836745; PubMed Central PMCID: PMC1552081

18. Nomura AM, Kolonel LN, Miki K, Stemmermann GN, Wilkens LR, Goodman MT, et al. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. The Journal of infectious diseases. 2005; 191(12):2075–81. doi: 10.1086/430353 PMID: 15897993

19. Haneda M, Kato M, Ishigaki S, Suzuki M, Takahashi M, Nakagawa M, et al. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori. Journal of gastroenterology and hepatology. 2013; 28(1):78–83. Epub 2012/10/05. doi: 10.1111/j.1440-1746.2012.07285.x PMID: 23034090
22. Kikuchi R, Abe Y, Iijima K, Koike T, Ara N, Uno K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. The Tohoku journal of experimental medicine. 2011; 223(1):35–44. PMID: 2122340

23. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. European journal of gastroenterology & hepatology. 2012; 24(1):37–41. doi: 10.1097/MEG.0b013e32834d0a0a PMID: 21989121

24. Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2008; 13(2):146–56. doi: 10.1111/j.1523-5788.2008.00592.x PMID: 18321304

25. Zhang XM, Li JX, Zhang GY, Li XH, Gu H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC gastroenterology. 2014; 14:3. Epub 2014/01/05. doi: 10.1186/1471-230x-14-3 PMID: 24383519; PubMed Central PMCID: PMCPMC3893558

26. Mizuno S, Kobayashi M, Tominaka S, Miki J, Masuda A, Onoyama M, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2009; 12 (3):158–63. Epub 2009/11/06. doi: 10.1007/s10120-009-0522-y PMID: 19890696

27. Huang YY, Cheng WC, Gao N, Ye N, Qian YT. The diagnostic value of serum pepsinogen I and II for gastric cancer and precancerous lesions of gastric cancer detection. Chinese journal of Internal Medicine. 2013; 52(4):332–3. doi: 10.3760/cma.j.issn.0578-1426.2013.04.017

28. Yu ZL, Ji M, Yang X, Zhang PT, Huang XJ, Zhang ZY, et al. Serum pepsinogen detection in gastric cancer screening. Chinese journal of digestive endoscopy. 2008; 25(10):512–5. doi: 10.3760/cma.j.issn.1007-5222.2008.10.003

29. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol. 1998; 93(7):1090–4. doi: 10.1111/j.1572-0241.1998.00335.x PMID: 9672336

30. Chang FY, Lai KH, Wang TF, Lee SD, Tsai YT, Tsay SH. Location and type of gastric carcinoma in relation to pepsinogen I level in blood. Scandinavian journal of gastroenterology. 1992; 27(10):884–8. PMID: 1439542

31. Agkoc M, Dursun H, Albayrak F, Yilmaz O, Kiziltunc A, Yilmaz A, et al. Usefulness of serum pepsinogen levels as a screening test for atrophic gastritis and gastric cancer. Eurasian J Med. 2010; 42(1):15–8. doi: 10.5152/ejem.2010.05 PMID: 25610111; PubMed Central PMCID: PMC4261308

32. Aoki K, Misumi J, Kimura T, Zhao W, Xie T. Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen I, II and of PG I/PG II ratios in a gastric cancer case-control study. Journal of epidemiology / Japan Epidemiological Association. 1997; 7(3):143–51. PMID: 9337512

33. Oksanen A, Sipponen P, Miettinen A, Sama S, Rautelin H. Evaluation of blood tests to predict normal gastric mucosa. Scandinavian journal of gastroenterology. 2000; 35(8):791–5. PMID: 10994615

34. He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. Journal of gastroenterology and hepatology. 2011; 26(6):1039–46. doi: 10.1111/j.1440-1746.2011.06692.x PMID: 21303408

35. Aulia D, Manz GO, Simadibrata M. Pepsinogen I concentration in organic dyspepsia patients at Gastroenterology Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital. Acta Med Indones. 2009; 41(3):107–14. PMID: 19752461

36. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, et al. Serum biomarker tests are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Journal of gastroenterology and hepatology. 2012; 24(1):37–41. doi: 10.1111/j.1440-1746.2011.06692.x PMID: 21303408

37. Chae H, Lee JH, Lim J, Kim M, Kim Y, Han K, et al. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis]. Korean J Lab Med. 2008; 28(3):201–6. doi: 10.3343/kjl.2008.28.3.201 PMID: 18594172

38. Sierra R, Une C, Ramirez V, Gonzalez MI, Ramirez JA, de Mascarel A, et al. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clinical and experimental medicine. 2006; 6(2):72–8. doi: 10.1007/s10238-006-0098-3 PMID: 16820994

39. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia. 2004; 6 (5):449–56. doi: 10.1593/neo.03505 PMID: 15548353; PubMed Central PMCID: PMC1531649

40. Wu KC, Li HT, Qiao TD, Li CN, Ji WS, Tian FQ, et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis. 2004; 5(1):22–7. PMID: 15612668

PLOS ONE | DOI:10.1371/journal.pone.0142080 November 10, 2015 21 / 23
41. Brouet N, Plebani M, Sakarowitch C, Sipponen P, Megraud F, Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003; 88(8):1239–47. doi: 10.1038/sj.bjc.6600877 PMID: 12698190; PubMed Central PMCID: PMC2747577

42. Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Med J Islam Repub Iran. 2014; 28:150. PMID: 25695008; PubMed Central PMCID: PMC4322333

43. Keikki M, Samloff IM, Varis K, Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl. 1991; 186:109–16. PMID: 1759117

44. Nardone G, Rocco A, Staibano S, Mezza E, Autiero G, Compare D, et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther. 2005; 22(11–12):1139–46. doi: 10.1111/j.1365-2036.2005.02734.x PMID: 16305728

45. Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1998; 7(3):261–3. PMID: 9521444

46. Sitas F, Smallwood R, Jewell D, Millard PR, Newell DG, Meuwissen SG, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1993; 2(2):119–23. PMID: 8467246

47. Thakkar H, Davey CL, Medcalf EA, Skingle L, Craig AR, Newman DJ, et al. Stabilization of turbidimetric immunoassay by covalent coupling of antibody to latex particles. Clinical chemistry. 1991; 37(7):1248–51. Epub 1991/07/01. PMID: 1655297

48. Huang M, Tang AG, Mu S, Yang JJ, Xiang ZY, Liu B, et al. Serum pepsinogen reference intervals in apparently healthy Chinese population with latex enhanced turbidimetric immunoassay. Journal of clinical pathology. 2014; 67(4):350–4. doi: 10.1136/jclinpath-2013-201942 PMID: 24170207

49. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87–108. doi: 10.3322/caac.21262 PMID: 25651787

50. Huang YK, Yu JC. Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review. World journal of gastroenterology: WJG. 2015; 21(34):9863–86. doi: 10.3748/wjg.v21.i34.9863 PMID: 26379393; PubMed Central PMCID: PMC4566381

51. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer research and treatment: official journal of Korean Cancer Association. 2005; 37(6):325–31. Epub 2005/12/01. doi: 10.4143/crt.2005.37.6.325 PMID: 19956367; PubMed Central PMCID: PMC4012276

52. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007; 12(1):1–15. doi: 10.1111/j.1523-5378.2007.00475.x PMID: 17241295

53. Ley C, Mohar A, Guamer J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev. 2001; 10(2):107–12. PMID: 11219766

54. Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined detection of CEA, CA 19–9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pacific journal of cancer prevention. APJCP. 2014; 15(15):6295–300. Epub 2014/08/16. PMID: 25124614

55. Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015. doi: 10.1136/gutjnl-2014-308585 PMID: 26258994

56. Pak CH, Kim EH, Jung DH, Chung H, Park JC, Shin SK, et al. The new modified ABCD method for gastric neoplasm screening. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015. doi: 10.1007/s10120-015-0473-4 PMID: 25663259

57. Aliouk S, Ohmoto Y, Gunji T, Matsushashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011; 141(3):837–45 e1-7. doi: 10.1053/j.gastro.2011.06.040 PMID: 21699780; PubMed Central PMCID: PMC3163741

58. Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC gastroenterology. 2014; 14:74. doi: 10.1186/1471-230X-14-74 PMID: 24720760; PubMed Central PMCID: PMC4012276

59. Syrrjanen KJ, Sipponen P, Harkonen M, Peetsalu A, Korpela S. Accuracy of the GastroPanel test in the detection of atrophic gastritis. European journal of gastroenterology & hepatology. 2015; 27(1):102–4. doi: 10.1097/MEG.0000000000000215 PMID: 25426982; PubMed Central PMCID: PMC4337584
60. McNicholl AG, Forne M, Barrio J, De la Coba C, Gonzalez B, Rivera R, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European journal of gastroenterology & hepatology. 2014; 26(9):941–8. doi:10.1097/MEG.0000000000000132 PMID: 25014624; PubMed Central PMCID: PMC4232299

61. Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio—a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology. 2004; 51(9):1249–54. PMID: 15362725

62. Sadjadi A, Yazdanbod A, Lee YY, Borei M, Samadi F, Alizadeh BZ, et al. Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis. PloS one. 2013; 8(9):e74440. doi:10.1371/journal.pone.0074440 PMID: 24098650; PubMed Central PMCID: PMC3787044

63. Penno MA, Klingler-Hoffmann M, Brazzatti JA, Boussioutas A, Putoczki T, Ernst M, et al. 2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. Journal of proteomics. 2012; 77:40–58. doi:10.1016/j.jprot.2012.07.002 PMID: 22789672

64. Pals G, Rasanen V, Meuwissen SG, Frants RR, Kostense PJ, Eriksson AW. Enzyme-linked immunosorbent assay and radioimmunoassay of serum pepsinogen A. Scand J Clin Lab Invest. 1987; 47(1):29–33. PMID: 3554488

65. Yang SK, Xiao L, Zhang H, Xu XX, Song PA, Liu FY, et al. Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: a systematic review and meta-analysis. BMC infectious diseases. 2014; 14:452. Epub 2014/08/26. doi:10.1186/1471-2334-14-452 PMID: 25145785; PubMed Central PMCID: PMCPMC4155125

66. Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014; 20(2):105–13. doi:10.1111/1469-0691.12474 PMID: 24274632

67. Lin F, Tan HJ, Guan JS, Lim YP. Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery. Expert review of proteomics. 2014; 11(4):515–30. Epub 2014/04/02. doi:10.1586/14789450.2014.904751 PMID: 24684179